A clinical program from the Thoracic Oncology Group of Australasia (TOGA), called ‘ASPiRATION’, which aims to assess the impact of personalised healthcare in lung cancer, has been jointly funded by Government and industry in a five-way partnership with research and academia.
The initiative is between the Thoracic Oncology Group of Australasia (TOGA), the Australian Genomic Cancer Medicine Centre (AGCMC), and the NHMRC Clinical Trials Centre (CTC). The Australian Government will commit $5 million towards the study through the Medical Research Future Fund (MRFF); while Roche will contribute $7.135 million plus in-kind support with access to Roche medicines via clinical trials.
Lung cancer is the fifth most commonly diagnosed cancer and the leading cause of cancer death in Australia. Compared to the other four most commonly diagnosed cancers, lung cancer has the lowest five-year relative survival rate at just 17 per cent.
The ASPiRATION study will be the first of its kind in Australia to generate high-quality, real-world, clinical and medical data about the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC). PHC uses more powerful genomic diagnostic tools and precise treatments by leveraging our increasingly sophisticated understanding of differences among patients, diseases and medicines.
